Loading...
Market
What will be the primary indication for TECELRA® usage by end of 2024?
2
Resolution / Starting Odds
Advanced Synovial Sarcoma • 25%
Other Sarcomas • 25%
Other Solid Tumors • 25%
Combination Therapies • 25%
Clinical data and usage reports from Adaptimmune
Story
FDA Grants Accelerated Approval to Adaptimmune's TECELRA® for Advanced Synovial Sarcoma
Aug 1, 2024, 06:03 PM
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Adaptimmune's TECELRA® (afamitresgene autoleucel), marking it as the first approved engineered cell therapy for a solid tumor. This milestone approval extends the power of immunotherapies into difficult-to-reach sarcomas, specifically targeting advanced synovial sarcoma, a rare cancer that arises in the body's soft tissues. Adaptimmune's TECELRA® is also noted as a significant development in TCR gene therapy.
View original story
Similar markets
Less than 100 • 25%
100 - 500 • 25%
500 - 1000 • 25%
More than 1000 • 25%
No reports • 25%
Mild side effects • 25%
Moderate side effects • 25%
Severe side effects • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Weight Reduction • 25%
Cardiovascular Benefits • 25%
Diabetes Management • 25%
Other • 25%
Dental implants alternative • 25%
Cosmetic dentistry • 25%
Orthodontic applications • 25%
Other • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
B-cell malignancies • 25%
Autoimmune diseases • 25%
Both • 25%
Neither • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%
Weight Loss • 25%
Type 2 Diabetes • 25%
Both equally • 25%
Other • 25%